<DOC>
	<DOCNO>NCT02167139</DOCNO>
	<brief_summary>This randomise , double-blind , parallel group , multicentre clinical study evaluate efficacy , safety , tolerability , pharmacokinetics immunogenicity SB5 compare Humira® subject moderate severe RA despite MTX therapy .</brief_summary>
	<brief_title>A Study Comparing SB5 Humira® Subjects With Moderate Severe Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>Investigational product : SB5 40 mg ( 0.8 mL 50 mg/mL ) Indication study : Rheumatoid arthritis</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Are male female age 1875 year time signing informed consent form . Have diagnose RA accord revised 1987 American College Rheumatology ( ACR ) criteria least 6 month exceed 15 year prior Screening . Have moderate severe active disease despite MTX therapy define : 1 . More equal six swollen joint equal six tender joint ( 66/68 joint count system ) Screening Randomisation . 2 . Either erythrocyte sedimentation rate ( Westergren ) ≥ 28 mm/h serum Creactive protein ≥ 10 mg/dL Screening . Must treat MTX total least 6 month prior Randomisation must : stable route administration ( oral parenteral ) stable dose MTX ( 1025 mg/week ) least 4 week prior Screening . Female subject pregnant nursing Screening Randomisation plan become pregnant Screening 5 month last dose IP . Have treat previously biological agent include tumour necrosis factor inhibitor . Have know hypersensitivity human immunoglobulin proteins component Humira SB5 . Have positive serological test hepatitis B hepatitis C know history infection human immunodeficiency virus . Have current diagnosis active tuberculosis ( TB ) , recently expose person active TB , consider latent TB . Have serious infection treat intravenous antibiotic infection within 8 week oral antibiotic within 2 week prior Randomisation . Have history chronic recurrent infection . Have follow condition : 1 . History congestive heart failure ( New York Heart Association Class III/IV ) . 2 . History acute myocardial infarction unstable angina within previous 12 month prior Screening . 3 . History demyelinate disorder . 4 . History malignancy within previous 5 year prior Screening . 5 . History lymphoproliferative disease include lymphoma . 6 . Any disease disorder , opinion Investigator , put subject risk enrol . Have physical incapacitation ( ACR functional Class IV wheelchair/bedbound ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid Arthritis , Adalimumab</keyword>
</DOC>